	Application No.	Applicant(s)
Notice of Allowability	10/549,972	ALBERTI ET AL.
	Examiner	Art Unit
	JEFFREY H. MURRAY	1624
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to 4/17/2008.		
2. ☑ The allowed claim(s) is/are <u>1,7,9 and 14</u> .		
3. Acknowledgment is made of a claim for foreign priority ur  a) All b) Some* c) None of the:  1. Certified copies of the priority documents have  2. Certified copies of the priority documents have  3. Copies of the certified copies of the priority documents have  International Bureau (PCT Rule 17.2(a)).  * Certified copies not received:  Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	e been received. e been received in Application No cuments have been received in this r	national stage application from the
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1. Notice of References Cited (PTO-892)	5. Notice of Informal Page 1	atent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	<ol> <li>Interview Summary Paper No./Mail Dat</li> </ol>	
3. Information Disclosure Statements (PTO/SB/08),	7. Examiner's Amend	nent/Comment
Paper No./Mail Date <u>9/20/2005</u> 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	<ol> <li>8.</li></ol>	ent of Reasons for Allowance
	/James O. Wilson/ Supervisory Patent Examin Art Unit 1624	er

Application/Control Number: 10/549,972 Page 2

Art Unit: 1624

# **DETAILED ACTION**

#### Status of Claims

1. Claims 1, 7, 9, and 14 are pending in this application. Claims 2-6, 8, 10-13 and 15 have been cancelled. This action is in response to the applicants' application filed on September 20, 2005.

### **Examiner's Amendment**

- 2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.
- a) The title was changed from "Chemical compounds" to "Aminopyrazine derivatives and compositions."

### Reasons for Allowance

3. The following is an examiner's statement of reasons for allowance:

The current application is free of the prior art. The closet prior art is Harbeson, et. al., WO 2003066629. Harbeson, et. al. teaches an aminopyrazine which is bonded to a benzoimidazole, for example, 5-(3-methoxyphenyl)-3-[1-(2-methylpropyl)-1H-benzimidazol-2-pyrazineamine. The current application overcomes the benzimidazole with a fused imidazole-pyridine rings to generate an aminopyrazine bonded to an imidazopyridine, for instance N-[4-[5-amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-2-pyrazinyl]phenyl]-methanesulfonamide.

Application/Control Number: 10/549,972 Page 3

Art Unit: 1624

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee, and to avoid delays, should preferably accompany the issue fee. Such submissions should clearly be labeled "Comments on the Statements of Reasons for Allowance".

# Conclusion

- 4. Claims 1, 7, 9, and 14 are allowed.
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey H. Murray, J.D., whose telephone number is 571-272-9023. The examiner can normally be reached on Mon.-Thurs. 7:30-6pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson can be reached at 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Jeffrey H Murray/ Patent Examiner Art Unit 1624 . /James O. Wilson/ Supervisory Patent Examiner Art Unit 1624